{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:55:04Z","timestamp":1788998104608,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFA1308900"],"award-info":[{"award-number":["2025YFA1308900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFA0922703"],"award-info":[{"award-number":["2025YFA0922703"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijbiomac.2026.151878","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:41:45Z","timestamp":1775493705000},"page":"151878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A rationally designed bispecific antibody targeting GPC3 and PD-L1 induces tumor-directed immune activation and cytotoxicity"],"prefix":"10.1016","volume":"360","author":[{"given":"Rui","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-4646","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151878_bb0010","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151878_bb0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s43018-025-00918-1","article-title":"Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma \u2013 a multicenter phase 2 trial (EPOC1802)","volume":"6","author":"Bando","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2147\/CMAR.S325514","article-title":"Combination atezolizumab, cobimetinib, and vemurafenib as a treatment option in BRAF V600 mutation-positive melanoma: patient selection and perspectives","volume":"16","author":"Dugan","year":"2024","journal-title":"Cancer Manag. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17425255.2017.1277204","article-title":"Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma","volume":"13","author":"Patel","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151878_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189334","article-title":"PD-1\/PD-L1 blockade therapy in hepatocellular carcinoma: current status and potential biomarkers","volume":"1880","author":"Xu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J. Emerg. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.151878_bb0045","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151878_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151878_bb0060","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73 Suppl 1(Suppl 1)","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0080","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/JHC.S347932","article-title":"Safety and efficacy of atezolizumab and bevacizumab combination as a first line treatment of advanced hepatocellular carcinoma","volume":"10","author":"Zanuso","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-017-3241-9","article-title":"Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)","volume":"79","author":"Abou-Alfa","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00108","article-title":"Immunotherapeutic targeting of GPC3 in pediatric solid embryonal tumors","volume":"9","author":"Ortiz","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0100","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","article-title":"The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential","volume":"29","author":"Devan","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114391","article-title":"GPC-3 in hepatocellular carcinoma; a novel biomarker and molecular target","volume":"444","author":"Tehrani","year":"2025","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-06-1025","article-title":"Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma","volume":"13","author":"Jia","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109383","article-title":"Research progress of drugs targeting GPC3 in cancer therapy","volume":"169","author":"Li","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0125","article-title":"Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma","volume":"12\u20132022","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-12-2616","article-title":"First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0150","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0155","series-title":"A bispecific antibody targeting human Claudin18.2 and human PD-L1 proteins and use thereof","author":"Qu","year":"2021"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151878_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101420","article-title":"A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy","volume":"297","author":"Chen","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24767-5","article-title":"A human CD137\u00d7PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade","volume":"12","author":"Geuijen","year":"2021","journal-title":"Nat. Commun."},{"issue":"Suppl. 2","key":"10.1016\/j.ijbiomac.2026.151878_bb0170","article-title":"544 a phase I\/II clinical trial of anti-CLDN18.2\/PD-L1 recombinant humanized bispecific antibody Q-1802 combined with XELOX chemotherapy in untreated advanced GC\/GEJ patients","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0175","article-title":"Development of a bispecific IgG1 antibody targeting BCMA and PDL1","volume":"13","author":"Cattaneo","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151878_bb0180","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1466016","article-title":"A novel bispecific antibody for EGFR-directed blockade of the PD-1\/PD-L1 immune checkpoint","volume":"7","author":"Koopmans","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/srep40098","article-title":"Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence","volume":"7","author":"Mazor","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151878_bb0200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4161\/mabs.21379","article-title":"Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies","volume":"4","author":"Klein","year":"2012","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151878_bb0205","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1080\/19420862.2018.1505398","article-title":"Characterization and analysis of scFv-IgG bispecific antibody size variants","volume":"10","author":"Cao","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0210","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-12-416039-2.00002-1","article-title":"Chapter two - Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting","author":"Gu","year":"2012"},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ddtec.2020.10.002","article-title":"Recent advancements in DVD-Ig based therapeutic development","volume":"34","author":"Dong","year":"2019","journal-title":"Drug Discov. Today Technol."},{"issue":"32","key":"10.1016\/j.ijbiomac.2026.151878_bb0220","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.1905646116","article-title":"A tumor-targeted immune checkpoint blocker","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0225","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4161\/mabs.1.4.8755","article-title":"Molecular construction and optimization of anti-human IL-1alpha\/beta dual variable domain immunoglobulin (DVD-Ig) molecules","volume":"1","author":"Wu","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115434","article-title":"Rational design of a bispecific antibody for rapid and prolonged neutrophil mobilization and proliferation","volume":"165","author":"Deng","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0235","article-title":"The use of ex vivo whole-organ imaging and quantitative tissue histology to determine the biodistribution of fluorescently labeled molecules","volume":"118","author":"McGowan","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0240","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4142\/jvs.2013.14.4.473","article-title":"Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice","volume":"14","author":"Hue","year":"2013","journal-title":"J. Vet. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0250","series-title":"Antibody Engineering","first-page":"239","article-title":"Generation and characterization of a dual variable domain immunoglobulin (DVD-Ig\u2122) molecule","author":"Wu","year":"2010"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/eji.1830180221","article-title":"The half-lives of serum immunoglobulins in adult mice","volume":"18","author":"Vieira","year":"1988","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151878_bb0265","article-title":"Delivery of drugs into cancer cells using antibody-drug conjugates based on receptor-mediated endocytosis and the enhanced permeability and retention effect","volume":"11","author":"Tashima","year":"2022","journal-title":"Antibodies (Basel)"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.151878_bb0270","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1074\/jbc.M116.714287","article-title":"A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets","volume":"291","author":"Rhoden","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"41","key":"10.1016\/j.ijbiomac.2026.151878_bb0275","doi-asserted-by":"crossref","first-page":"24689","DOI":"10.1074\/jbc.M115.651653","article-title":"Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor \u00d7 c-MET bispecific antibody","volume":"290","author":"Jarantow","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151878_bb0280","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s11095-024-03803-1","article-title":"Exploring multivalency in the development of anti-PD-L1 peptides for cancer immunotherapy","volume":"41","author":"Mamani","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0285","article-title":"B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0290","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12935-021-02081-w","article-title":"Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients","volume":"21","author":"Deng","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151878_bb0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2326-6066.CIR-16-0148","article-title":"Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma","volume":"5","author":"Nowicki","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151878_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104181","article-title":"Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment","volume":"29","author":"Hu","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151878_bb0305","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nri3311","article-title":"Humanized mice for immune system investigation: progress, promise and challenges","volume":"12","author":"Shultz","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151878_bb0310","first-page":"153","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151878_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2017.1389364","article-title":"Safety testing of monoclonal antibodies in non-human primates: case studies highlighting their impact on human risk assessment","volume":"10","author":"Brennan","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2026.151878_bb0320","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12\u20132024","author":"Madsen","year":"2024","journal-title":"Front. Bioeng. Biotechnol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026018040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026018040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:42:30Z","timestamp":1777956150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026018040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"alternative-id":["S0141813026018040"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151878","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rationally designed bispecific antibody targeting GPC3 and PD-L1 induces tumor-directed immune activation and cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151878"}}